Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001209191-24-003230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-13 | 2024-02-09 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +344.6K | 1.12M | +44% | $0 |
| D | 2024-02-13 | 2024-02-09 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $10.09 | -3,233 | 1.12M | -0.3% | -$32.6K |
| D | 2024-02-13 | 2024-02-09 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +666.9K | 666.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-02-09 | A | A | 11,148 | $0.00 | 785,851 | D | — | — | |
| 2 | Common | Class A Common Stock | 2024-02-09 | A | A | 333,449 | $0.00 | 1,119,300 | D | — | — | |
| 3 | Common | Class A Common Stock | 2024-02-09 | F | D | 3,233 | $10.09 | 1,116,067 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-02-09 | A | A | 666,898 | $0.00 | 666,898 | D | $10.09 · — to 2034-02-09 | 666,898 Class A Common Stock | (F11) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |